By Hendra Lukman 
Researchers at Duke University have identified a key enzyme, kinase STK17B, that plays a critical role in the survival of multiple myeloma (MM) cancer cells by suppressing a natural cell death process called ferroptosis. This groundbreaking discovery not only demonstrates that blocking STK17B can directly kill these aggressive cancer cells but also significantly enhances the efficacy of existing treatments. The findings, published on September 12 in the prestigious journal Blood, offer a promising new avenue for combating this challenging blood cancer, which is notoriously difficult to treat, particularly in its relapsed and drug-resistant forms.
Multiple myeloma, a relentless cancer of plasma cells, poses a significant global health burden. Plasma cells, a vital component of the immune system, are responsible for producing antibodies to combat infections. In multiple myeloma, however, these cells become malignant, proliferating uncontrollably within the bone marrow. This unchecked growth disrupts the production of healthy blood cells, weakens the immune system, and can lead to severe complications such as kidney damage and painful bone disease. Globally, multiple myeloma accounts for approximately 10% of all diagnosed blood cancers. While advancements in targeted therapies have improved patient outcomes, the persistent challenge of relapsed disease and the emergence of drug-resistant myeloma necessitate the development of novel therapeutic strategies.
The research team at Duke University delved into the complex mechanisms by which cancer cells evade natural death processes. They observed a recurring phenomenon in multiple myeloma: the suppression of ferroptosis. Ferroptosis is a regulated form of cell death characterized by the accumulation of excess iron within cells, leading to oxidative damage to cell membranes and subsequent cell breakdown. Cancer cells, however, often exhibit an uncanny ability to thrive in iron-rich environments that would be toxic to normal cells. This resilience, researchers believed, was due to an active suppression of ferroptosis.
"Cancer cells live like there is no tomorrow," stated Mikhail Nikiforov, a professor of pathology and biomedical engineering at Duke and the senior author of the study. "They accumulate iron at levels that would normally be toxic and tear cells apart, but that wasn’t what we observed. Instead, these cancer cells adapted to resist the type of cell death triggered by iron overload, and the mechanisms behind this suppression were largely unknown." This long-standing question has now been answered by Nikiforov and his collaborators.
Unraveling the Role of STK17B in Ferroptosis Suppression
The Duke research team meticulously investigated the molecular machinery responsible for this ferroptosis resistance in multiple myeloma. Their extensive work pinpointed kinase STK17B as the pivotal enzyme orchestrating this survival mechanism. Traditionally recognized for its involvement in cell death pathways and T-cell activation, STK17B was found to play an equally crucial role in maintaining iron homeostasis within cancer cells. The enzyme achieves this by regulating the delicate balance of proteins that either promote (pro-ferroptotic) or inhibit (anti-ferroptotic) ferroptosis.
The study revealed a direct correlation between elevated levels of STK17B and poorer patient prognoses. "Elevated levels of STK17B are associated with poor overall survival in MM patients," Nikiforov emphasized. Furthermore, the research highlighted the enzyme’s particular prominence in cases of relapsed disease, directly underscoring its significant contribution to therapy resistance. This observation provides a critical insight into why current treatments may lose their effectiveness over time.
A Novel Therapeutic Approach: Inhibiting STK17B
With the identification of STK17B as the key culprit, the researchers turned their attention to developing strategies to counteract its effects. A pivotal moment in their research involved the utilization of a novel compound developed by Timothy Willson, the Harold Kohn Distinguished Professor in Open Science Drug Discovery at the UNC Eshelman School of Pharmacy. This compound was specifically designed to inhibit the enzymatic activity of STK17B.
By employing this inhibitor, the Duke team successfully disrupted STK17B’s control over iron accumulation within multiple myeloma cells. This intervention effectively reactivated the dormant ferroptosis pathway, triggering cell death in the malignant plasma cells. Crucially, the researchers observed a synergistic effect: not only did inhibiting STK17B induce cancer cell death, but it also rendered these cells significantly more vulnerable to conventional multiple myeloma therapies. This suggests a potential paradigm shift in treatment, where a combination of STK17B inhibition and existing therapies could achieve superior outcomes.
Pre-clinical Success and Future Prospects
To validate their findings, Nikiforov’s team conducted pre-clinical trials using an oral formulation of the STK17B inhibitor in mouse models of multiple myeloma. The results were highly encouraging. The compound effectively induced ferroptosis by increasing the uptake of iron into cancer cells, thereby starving them of essential nutrients and triggering their demise. Moreover, this intervention led to a significant reduction in tumor growth within the treated mouse models.
"These findings establish that STK17B is a critical safeguard protecting MM cells from the toxic consequences of their iron independence," Nikiforov declared. "Inhibiting this kinase holds much promise as a therapeutic strategy." The successful translation of these findings from laboratory experiments to animal models represents a significant leap forward in the quest for more effective multiple myeloma treatments.
The implications of this research extend beyond multiple myeloma. The study’s findings suggest that STK17B’s role in ferroptosis suppression may not be exclusive to this particular cancer. "Many other types of cancer cells are also resistant to ferroptosis," Nikiforov noted. "We’re curious to see how this inhibitor could improve therapies for other tumors outside of multiple myeloma." This opens up exciting possibilities for exploring the STK17B inhibitor as a potential therapeutic agent for a broader spectrum of cancers that exhibit similar resistance mechanisms.
A Path Towards Commercialization and Broader Application
The Duke research team is actively pursuing the development of this promising therapy. They have already filed a provisional patent based on their discoveries, with the ultimate goal of commercializing the treatment. This strategic move signals a strong commitment to translating scientific breakthroughs into tangible benefits for patients.
Beyond the immediate focus on refining the formulation and advancing clinical trials, the researchers are also keen to explore the broader applications of their findings. Understanding how the STK17B inhibitor influences drug resistance in other cancers is a key area of future investigation. This could involve studying its impact on therapies for solid tumors or other hematological malignancies that have proven recalcitrant to conventional treatments.
Supporting Data and Context
Multiple myeloma (MM) is a complex and heterogeneous disease. The American Cancer Society estimates that in 2023, approximately 34,700 new cases of multiple myeloma will be diagnosed in the United States, and about 12,830 people will die from it. The median age at diagnosis is around 69 years, with the disease being more common in men and in African Americans. While treatments have improved, the five-year relative survival rate for multiple myeloma, which was about 30% in the mid-1970s, has now risen to about 56%. However, this figure can vary significantly depending on the stage of the disease at diagnosis and the patient’s response to treatment. The emergence of drug resistance, often driven by the selection of cancer cells with specific survival mechanisms like the one identified in this study, remains a significant hurdle in achieving long-term remission.
The concept of ferroptosis has gained considerable traction in cancer research over the past decade. Initially described in 2012, ferroptosis is distinct from other forms of programmed cell death like apoptosis and autophagy. Its dependence on iron and the production of lipid reactive oxygen species makes it a unique target for cancer therapy. The identification of specific genes and pathways that regulate ferroptosis, such as the glutathione peroxidase 4 (GPX4) pathway, has been crucial in understanding its role in disease. The Duke study adds STK17B to this growing list of critical regulators, providing a specific molecular target for intervention.
Chronology of Research
- Early observations: Researchers noted that multiple myeloma cells often exhibit resistance to ferroptosis, a cell death pathway triggered by iron overload. The underlying mechanisms for this resistance remained largely unknown.
- Identification of STK17B: Through extensive investigation, a Duke University research team, led by Mikhail Nikiforov, identified kinase STK17B as a key enzyme responsible for suppressing ferroptosis in multiple myeloma cells.
- Correlation with prognosis: The study revealed that elevated STK17B levels are associated with poorer overall survival and are particularly pronounced in relapsed multiple myeloma cases, indicating its role in therapy resistance.
- Development of an inhibitor: Collaborating with Timothy Willson at UNC Eshelman School of Pharmacy, the team utilized a compound designed to inhibit STK17B.
- Pre-clinical validation: In mouse models of multiple myeloma, administration of the STK17B inhibitor induced ferroptosis, increased cancer cell iron uptake, and significantly reduced tumor growth.
- Enhanced efficacy with existing therapies: The study also demonstrated that inhibiting STK17B made cancer cells more sensitive to conventional multiple myeloma treatments.
- Publication and patent filing: The research findings were published in the journal Blood on September 12, and a provisional patent has been filed to commercialize the potential therapy.
- Future research: The team plans to further optimize the formulation and explore the inhibitor’s potential application in treating other ferroptosis-resistant cancers.
Broader Impact and Implications
The implications of this research are far-reaching. For patients battling multiple myeloma, this discovery offers a beacon of hope for more effective and durable treatments. By targeting a fundamental mechanism of cancer survival, the STK17B inhibitor could potentially overcome resistance to existing therapies and improve patient outcomes.
Beyond multiple myeloma, the findings have the potential to revolutionize cancer treatment across a broader spectrum. If STK17B’s role in ferroptosis suppression is conserved in other cancers, this inhibitor could become a valuable tool in the oncologist’s arsenal against a variety of malignancies. This could lead to the development of novel combination therapies that enhance the efficacy of chemotherapy, immunotherapy, and radiation, ultimately improving the survival rates and quality of life for cancer patients worldwide.
The collaborative nature of this research, involving expertise from Duke University and the UNC Eshelman School of Pharmacy, underscores the importance of interdisciplinary approaches in scientific discovery. The funding secured from various prestigious institutions, including the National Institutes of Health, the National Cancer Institute, and the Paula and Rodger Riney Foundation, highlights the significant scientific and clinical interest in this area of research. The involvement of the Structural Genomics Consortium (SGC) also signifies the integration of fundamental structural biology into drug discovery efforts. This multifaceted support system is crucial for advancing complex biomedical research from the laboratory bench to the patient bedside.
The successful identification and targeting of STK17B represent a significant stride in our understanding of cancer cell biology and a promising advancement in the fight against multiple myeloma and potentially other challenging cancers. The journey from discovery to clinical application is often long and arduous, but the findings from Duke University provide a compelling foundation for continued progress.
